Search results | ucb


Partnering Agreements with UCB

This report provides all the information you require to better understand UCB and its partnering interests and activities over the past seven years.


Akorn to bid for an acquisition of UCB’s subsidiary

Akorn targets UCB’s subsidiary for acquisition for tax inversion. 


UCB is a top pharmaceutical company based in Brussels, Belgium

UCB Pharma; Combining biology and chemistry to crack the CNS market

UCB Pharma is a global biopharma company developing treatments for diseases of the immune and central nervous system.

UCB: M&A activity 2005-2013

UCB has announced 2 M&A deals since 2005, with the acquisition of Meizler and Schwarz Pharma.

UCB: Partnering activity 2005-2013

UCB, a global big pharmaceutical company, announced over 90 partnering / licensing deals since 2005, with fluctuations every year in partnering activity. The biopharmaceutical company focusses on prime therapeutic areas: immunology and CNS.

UCB: Company Profile

UCB, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Dealmakers weekly review – February 13 2012 – Eli Lilly, Roche, UCB, Janssen, Sistemix, TiGenics, Becton Dickinson, SDIX, Aldagen, Carefusion

The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value

Bioinformatics: recent life science partnering trend analysis

The bioinformatics partnering deal trend analysis 2009 to 2014 are reviewed in this article.

Royalty financing

A sale of rights to royalties for sale of the product which would have otherwise been due to the licensor…


Bioinformatics is the application of computer science and information technology to the field of biology and medicine.


Sorry, your search returned no results.


UCB and Neuropore partner for NPT200-11

Neuropore Therapies and UCB have entered into a world-wide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease

UCB sheds Kremers Urban Pharma

UCB Group is selling Kremers Urban Pharmaceuticals, to two private equity firms, Advent International and Avista Capital Partners, for $1.525 billion

IMS health and UCB form a pharma partnership

IMS Health becomes pharma partner with UCB to help deliver greater business insights and improved operations, leveraging IMS Health’s Nexxus Commercial Application Suite and the IMS One intelligent cloud.

UCB and Dermira agree an exclusive pharma licensing agreement

UCB and Dermira have entered into an exclusive pharma licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

Sanofi and UCB sign a pharma deal for $138 million

Sanofi and UCB have entered into a pharma deal for the discovery and development of innovative anti-inflammatory small molecules, which have the potential to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis.

Biogen Idec and UCB make a pharma alliance pact

Biogen Idec and UCB have signed exclusive pharma alliance agreements granting UCB the right to commercialize Biogen Idec products.

Biopharma partners Evotec and UCB have achieved first milestones

Evotec has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with biopharma partners, UCB in the field of immunology.

Vectura in co development agreement with UCB for immunomodulatory product

Vectura Group have entered into a collaboration for the co development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease

UCB secures partnership with UNITHER Pharma in asset purchase pharma deals pact

UCB, a big pharma/ big biotech company has agreed with UNITHER Pharmaceuticals, a leading pharmaceutical manufacturer, that UNITHER will acquire UCB’s manufacturing plant in Rochester, New York in an asset purchase pharma deals pact

UCB enters big pharma deals with IBM in personalized epilepsy care

UCB big pharma deals IBM and announces the completion of the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy.